Epcoritamab plus R-CHOP achieve high response rates in untreated high-risk DLBCL
Click Here to Manage Email Alerts
CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated high-risk diffuse large B-cell lymphoma and double-hit or triple-hit lymphoma, according to research presented at ASCO Annual Meeting.
The study, presented by Lorenzo Falchi, MD, evaluated 46 patients with previously untreated high-risk DLBCL , 11 of whom had double-hit or triple-hit lymphoma. Patients received 48 mg epcoritamab (DuoBody-CD3xCD20; Genmab, AbbVie) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone).
Of these patients, 100% had a response and 76% had a complete metabolic response. Double-hit or triple-hit patients had similar complete metabolic response results at 82%.
“In patients who completed the R-CHOP portion or the R-CHOP and epcoritamab maintenance portion, the overall response rate was 100%, and the complete metabolic response rate 84% and 89% respectively, suggesting that there is a conversion from partial to complete response as therapy precedes,” Falchi, an assistant attending at Memorial Sloan Kettering Cancer Center, said.
Falchi noted median durations of response, PFS and OS were not reached. Responses were durable; at 9 months, an estimated 96% of patients with complete metabolic response remained in complete metabolic response, according to researchers.
“At the median follow up of 14.2 months, the duration of response and the duration of complete response were both very favorable, at over 95%. Among patients with double-hit or triple-hit lymphoma, these results were very similar,” Falchi said.
Collapse
Falchi L, et al. Abstract 7519. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Click Here to Manage Email Alerts